ACRIGEN BIOSCIENCES, INC.
Kensington, CA · Founded 2019 · CIK 0001779315 · Biotech · Private
Anti-CRISPR proteins that enhance CRISPR-Cas9 genome editing efficiency by tethering repair DNA to increase homology-directed repair
acrigen.com →- Grants
- $2.0M
- 5 awards
- Sector median: 1
- Raised
- $775K
- 1 Form D · Jul 2019
- 87 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 8
- 0 granted · 8 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2019202020212022
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $775,000 | |
| Federal grant | National Science Foundation · Phase I · SBIR Phase I: Development of a safe gene editing system via CRISPR-Cas and Cas inhibitor co-delivery | $225,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Discovery and applications of CRISPR-Cas inhibitor proteins | $252,131 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of Safe in Utero Gene Editing Technology in Mice | $256,580 | |
| Federal grant | National Science Foundation · Phase II · SBIR Phase II: Development of a safe gene editing system via CRISPR-Cas and Cas inhibitor co-delivery | $1,000,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Enhancing CRISPR-mediated homology-directed repair using anti-CRISPR proteins | $256,580 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2360 | OLIGOMERIX INC | — | $2.9M |
| 2361 | Allinaire Therapeutics, LLC | — | $950K |
| 2362 | ECM Therapeutics, Inc. | — | $919K |
| 2363 | ACRIGEN BIOSCIENCES, INC. | — | $775K |
| 2364 | MARCH BIOSCIENCES INC | — | $22M |
| 2365 | Biodesy LLC | — | $350K |
| 2366 | Montara Therapeutics | — | $28M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Karen BoeziDirector
- Joseph Bondy-DenomyDirector
- David RabukaDirector · Executive Officer · Promoter
Patents
- Compositions And Methods For Enhanced Nucleic Acid Targeting Specificityapplication
- Engineered Acr Proteins For Modulating Crispr Activityapplication
- Compositions And Methods For Enhanced Nucleic Acid Targeting Specificityapplication
- Compositions And Methods For Enhanced Nucleic Acid Targeting Specificityapplication
- Compositions And Methods For Enhanced Nucleic Acid Targeting Specificityapplication
- Compositions And Methods For Enhanced Nucleic Acid Targeting Specificityapplication
- Engineered Acr Proteins For Modulating Crispr Activityapplication
- Engineered Acr Proteins For Modulating Crispr Activityapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.